Nature Communications · 2016 · 69 citations · 30 references
Life SciencesCardiologyMolecular BiologyCell SignalingPathophysiologySignal TransductionCardiac PhysiologyCardiovascular DiseaseCardiovascular PathophysiologyCardiovascular PhysiologyHeart FailureProtein Kinase CascadesExtracellular Signal-regulated Kinase PathwayHeart Failure Molecular MechanismsPi3k-akt Signaling PathwayTherapeutic Target IdentificationTherapeutic Target Validation
Although pathological cardiac hypertrophy represents a leading cause of morbidity and mortality worldwide, our understanding of the molecular mechanisms underlying this disease is still poor. Here, we demonstrate that suppressor of IKKɛ (SIKE), a negative regulator of the interferon pathway, attenuates pathological cardiac hypertrophy in rodents and non-human primates in a TANK-binding kinase 1 (TBK1)/AKT-dependent manner. Sike-deficient mice develop cardiac hypertrophy and heart failure, whereas Sike-overexpressing transgenic (Sike-TG) mice are protected from hypertrophic stimuli. Mechanistically, SIKE directly interacts with TBK1 to inhibit the TBK1-AKT signalling pathway, thereby achieving its anti-hypertrophic action. The suppression of cardiac remodelling by SIKE is further validated in rats and monkeys. Collectively, these findings identify SIKE as a negative regulator of cardiac remodelling in multiple animal species due to its inhibitory regulation of the TBK1/AKT axis, suggesting that SIKE may represent a therapeutic target for the treatment of cardiac hypertrophy and heart failure.
30
Long-Term Trends in the Incidence of and Survival with Heart Failure
Daniel Levy, Satish Kenchaiah, Martin G. Larson et al. · New England Journal of Medicine · 2002 · 2.2K citations · Full text